BBOT 8-K 2026-11-10

BridgeBio Oncology Therapeutics, Inc. (BBOT) 8-K dated 2026-11-10 — accession 0001193125-26-455506.

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ.

BBOT: BBOT Reports Third Quarter 2026 Financial Results and Update on Corpora…

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported BBOT revenue for 2026-06-30 was $3.6M. Net income was -$56.5M. Revenue was down 10.0% from 2026-03-31 to 2026-06-30. BBOT currently screens at market cap $610.4M.

Not investment advice. The BBOT SEC hub lists recent forms. The stock page is the research view.